Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Operating Expenses: 2010-2025

Historic Operating Expenses for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $18.8 million.

  • Anika Therapeutics' Operating Expenses fell 3.45% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 67.25%. This contributed to the annual value of $81.1 million for FY2024, which is 0.72% down from last year.
  • Per Anika Therapeutics' latest filing, its Operating Expenses stood at $18.8 million for Q3 2025, which was up 1.48% from $18.5 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Operating Expenses registered a high of $35.4 million during Q1 2023, and its lowest value of -$18.9 million during Q4 2023.
  • Moreover, its 3-year median value for Operating Expenses was $19.5 million (2024), whereas its average is $19.9 million.
  • As far as peak fluctuations go, Anika Therapeutics' Operating Expenses crashed by 146.33% in 2022, and later soared by 194.20% in 2024.
  • Anika Therapeutics' Operating Expenses (Quarterly) stood at $27.3 million in 2021, then crashed by 146.33% to -$12.6 million in 2022, then tumbled by 49.90% to -$18.9 million in 2023, then spiked by 194.20% to $17.8 million in 2024, then decreased by 3.45% to $18.8 million in 2025.
  • Its Operating Expenses stands at $18.8 million for Q3 2025, versus $18.5 million for Q2 2025 and $19.0 million for Q1 2025.